磁共振弹性成像联合FIB-4与FibroScan-谷草转氨酶诊断NASH相关显著纤维化的比较
该前瞻性队列研究纳入美国加州大学圣地亚哥分校234例和日本横滨市立大学314例接受肝活检的NAFLD患者,比较MEFIB(磁共振弹性成像联合FIB-4)与FAST(振动控制瞬时弹性成像联合受控衰减参数及谷草转氨酶)对显著纤维化(分期≥2)的诊断准确性。结果显示MEFIB的AUROC在两个队列中均显著高于FAST,且作为纳入或排除标准时具有更高的阳性预测值和阴性预测值。
要点
- MEFIB对显著纤维化的诊断准确性优于FAST。
- MEFIB纳入标准阳性预测值达91.2%-96.0%,排除标准阴性预测值达85.6%-92.8%。
- 结果支持采用两步策略检测NAFLD显著纤维化。
核心结论
- 在NAFLD患者中,MEFIB对显著纤维化的诊断准确性高于FAST,支持两步策略用于检测显著纤维化。
研究设计与样本
- 前瞻性队列研究,纳入美国加州大学圣地亚哥分校连续234例NAFLD患者(UCSD队列)和日本横滨市立大学独立队列314例,均接受肝活检、磁共振弹性成像和FibroScan检查。
主要发现
- UCSD队列中显著纤维化比例为29.5%,横滨队列为66.2%。
- UCSD队列MEFIB的AUROC为0.860(95%CI 0.81-0.91),显著高于FAST的0.757(95%CI 0.69-0.82),p=0.005。
- 横滨队列MEFIB的AUROC为0.899,FAST为0.724,p<0.001。
- 作为纳入标准时,MEFIB(MRE≥3.3 kPa且FIB-4≥1.6)的阳性预测值为91.2%-96.0%,FAST(≥0.67)为74.2%-89.2%。
- 作为排除标准时,MEFIB(MRE<3.3 kPa且FIB-4<1.6)的阴性预测值为85.6%-92.8%,FAST(≤0.35)为57.8%-88.3%。
关键数值与推荐
- MEFIB纳入标准:MRE≥3.3 kPa且FIB-4≥1.6;排除标准:MRE<3.3 kPa且FIB-4<1.6。
- FAST纳入标准:≥0.67;排除标准:≤0.35。
- 显著纤维化定义为肝纤维化分期≥2。
临床怎么用
- 对于NAFLD患者,可采用MEFIB作为无创工具检测显著纤维化,以识别药物治疗候选者。
- MEFIB的纳入和排除标准具有较高的阳性预测值和阴性预测值,有助于临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Patients with NAFLD with significant hepatic fibrosis (Stage ≥ 2) are at increased risk of liver-related morbidity and are candidates for pharmacologic therapies. In this study, we compared the diagnostic accuracy of MEFIB (the combination of magnetic resonance elastography [MRE] and Fibrosis-4 [FIB-4]) and FAST (FibroScan-aspartate aminotransferase; combined liver stiffness measurement by vibration-controlled transient elastography, controlled attenuation parameter, and aspartate aminotransferase) for detecting significant fibrosis. APPROACH AND RESULTS: This prospective cohort study included 234 consecutive patients with NAFLD who underwent liver biopsy, MRE, and FibroScan at the University of California San Diego (UCSD cohort) and an independent cohort (N = 314) from Yokohama City University, Japan. The primary outcome was diagnostic accuracy for significant fibrosis (Stage ≥ 2). The proportions of significant fibrosis in the UCSD and Yokohama cohorts were 29.5% and 66.2%, respectively. Area under the receiver operating characteristic curve (95% CI) of MEFIB (0.860 [0.81-0.91]) was significantly higher than that of FAST (0.757 [0.69-0.82]) in the UCSD cohort (p = 0.005), with consistent results in the Yokohama cohort (AUROC, 0.899 [MEFIB] versus 0.724 [FAST]; p < 0.001). When used as the rule-in criteria (MEFIB, MRE ≥ 3.3 kPa and FIB-4 ≥ 1.6; FAST ≥ 0.67), the positive predictive value for significant fibrosis was 91.2%-96.0% for MEFIB and 74.2%-89.2% for FAST. When used as the rule-out criteria (MEFIB, MRE < 3.3 kPa and FIB-4 < 1.6; FAST ≤ 0.35), the negative predictive value for significant fibrosis was 85.6%-92.8% for MEFIB and 57.8%-88.3% for FAST. CONCLUSIONS: MEFIB has higher diagnostic accuracy than FAST for significant fibrosis in NAFLD, and our results support the utility of a two-step strategy for detecting significant fibrosis in NAFLD.
引用
- Tamaki N, Imajo K, Sharpton S, et al. Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis. Hepatology. 2021. PMID: 34496054. doi:10.1002/hep.32145
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。